NGQ1 Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medicure Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.60 |
| 52 Week High | CA$1.10 |
| 52 Week Low | CA$0.53 |
| Beta | 0.87 |
| 11 Month Change | 5.26% |
| 3 Month Change | -14.29% |
| 1 Year Change | -40.59% |
| 33 Year Change | -4.76% |
| 5 Year Change | -81.82% |
| Change since IPO | -96.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| NGQ1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 12.1% | -0.2% | 0.8% |
| 1Y | -40.6% | -16.9% | 9.1% |
Return vs Industry: NGQ1 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: NGQ1 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| NGQ1 volatility | |
|---|---|
| NGQ1 Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NGQ1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NGQ1's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Albert Friesen | www.medicure.com |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia.
Medicure Inc. Fundamentals Summary
| NGQ1 fundamental statistics | |
|---|---|
| Market cap | €6.40m |
| Earnings (TTM) | -€1.79m |
| Revenue (TTM) | €14.26m |
0.4x
P/S Ratio-3.6x
P/E RatioIs NGQ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGQ1 income statement (TTM) | |
|---|---|
| Revenue | CA$20.93m |
| Cost of Revenue | CA$8.08m |
| Gross Profit | CA$12.85m |
| Other Expenses | CA$15.48m |
| Earnings | -CA$2.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 26, 2024
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 61.41% |
| Net Profit Margin | -12.56% |
| Debt/Equity Ratio | 0% |
How did NGQ1 perform over the long term?
See historical performance and comparison